Lake Street Maintains Buy on OncoCyte, Lowers Price Target to $6
Lake Street analyst Thomas Flaten maintains OncoCyte (NASDAQ:OCX) with a Buy and lowers the price target from $11 to $6.
Needham Maintains Buy on OncoCyte, Lowers Price Target to $4
Needham analyst Mike Matson maintains OncoCyte (NASDAQ:OCX) with a Buy and lowers the price target from $5 to $4.
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.
52 Biggest Movers From Yesterday
Gainers
Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion.
Mid-Afternoon Market Update: Dow Tumbles 150 Points; Yumanity Therapeutics Shares Plunge
Toward the end of trading Wednesday, the Dow traded down 0.45% to 35,210.04 while the NASDAQ fell 0.28% to 14,466.47. The S&P also fell, dropping, 0.29% to 4,563.94.
Mid-Day Market Update: US Stocks Turn Negative; Zogenix Shares Spike Higher
Midway through trading Wednesday, the Dow traded down 0.13% to 35,321.51 while the NASDAQ fell 0.53% to 14,430.41. The S&P also fell, dropping, 0.19% to 4,568.33.
35 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Zogenix, Inc. (NASDAQ: ZGNX) shares jumped 67.1% to $26.15 after the company announced it will be acquired by UCB for approximately $1.9 billion.